Fc and Glycoengineered Antibodies Research 2024-2035: Close to 250 Trials are Evaluating Fc and Glycoengineered Antibodies to Treat Myriad of Disease Indications – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Fc and Glycoengineered Antibodies Market: Industry Trends and Global Forecasts, till 2035: Distribution by Type of... Read more.
Frontier Announces Amendment to its Revolving Credit Facility
DALLAS–(BUSINESS WIRE)–Frontier Communications Parent, Inc. (NASDAQ: FYBR) (“Frontier” or the “Company”) today announced the execution of an... Read more.
Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
LEXINGTON, Mass.–(BUSINESS WIRE)–Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat... Read more.
Endava Announces Third Quarter Fiscal Year 2024 Results
Q3 FY2024 14.3% Year on Year Revenue Decrease to £174.4 million 11.8% Revenue Decrease at Constant Currency Diluted EPS £(0.03) compared to £0.42 in the prior... Read more.
$20.6 Billion Coating Additives Markets: Industry Trends and Global Forecasts Till 2035: Surge in Infrastructure, Automobile Sector and Demand for Sustainable Coating Additives – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Coating Additives Market: Industry Trends and Global Forecasts, till 2035: Distribution by Industry Served, Type of... Read more.
Guardant Health Stock Trading Temporarily Halted; FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening
PALO ALTO, Calif.–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Nasdaq has temporarily... Read more.
HDI Announces Strategic Fronting Partnership with Hallmark Financial Services, Inc.
CHICAGO–(BUSINESS WIRE)–HDI Global Insurance Company, the US subsidiary of international commercial insurer, HDI Global SE (HDI) is pleased to announce... Read more.
“A Meaningful Retirement: Beyond Finances” with Buckingham Advisors Slated
Free, educational session will focus on non-financial aspects of retirement planning DAYTON, Ohio–(BUSINESS WIRE)–#ameaningfulretirement–Retirement... Read more.
2seventy bio to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.–(BUSINESS WIRE)–2seventy bio, Inc. (Nasdaq: TSVT) announced today that members of the management team will present at the following... Read more.
iCell Gene Therapeutics Announces Positive Clinical Data from Investigator Initiated Phase 1 Trial Evaluating BCMA-CD19 Compound CAR in Patients with Systemic Lupus Erythematosus/Lupus Nephritis Published in Annals of the Rheumatic Diseases
– BCMA-CD19 compound CAR (cCAR) therapy was safe and well tolerated and achieved proof of concept of complete humoral reset delivering long-term medication-free... Read more.